Amrita Y. Krishnan, MD

Articles by Amrita Y. Krishnan, MD

BCMA-Targeting Bispecifics in Multiple Myeloma: Safety Profile

ByAmrita Y. Krishnan, MD,Sandy Wong, MD,Philippe Moreau, MD,Alfred Garfall, MD,Joshua Richter, MD

May 9th 2023

Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.

Multiple Myeloma: Selecting Among the BCMA-Targeting Therapies

ByAmrita Y. Krishnan, MD,Sandy Wong, MD,Philippe Moreau, MD,Alfred Garfall, MD,Joshua Richter, MD

May 2nd 2023

Shared insight on how experts select among the available BCMA-targeting bispecific antibodies and CAR T-cell therapies in patients with multiple myeloma.

The Evolving Role of BCMA-Targeting Bispecifics in Multiple Myeloma

ByAmrita Y. Krishnan, MD,Sandy Wong, MD,Philippe Moreau, MD,Alfred Garfall, MD,Joshua Richter, MD

May 2nd 2023

Expert panelists reflect on other clinical trials aimed at defining the role for BCMA-targeting bispecifics in multiple myeloma and consider how they would utilize this class of agents in real-world practice.

BCMA-Targeting Bispecifics in Multiple Myeloma: Teclistamab

ByAmrita Y. Krishnan, MD,Sandy Wong, MD,Philippe Moreau, MD,Alfred Garfall, MD,Joshua Richter, MD

April 26th 2023

Opening its discussion on BCMA-targeting bispecific antibodies in multiple myeloma, a panel of expert oncologists highlights key clinical data behind teclistamab.

Management of Bispecific Toxicities and Final Thoughts on Treatments in MM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

March 6th 2023

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

March 6th 2023

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Rationale for Bispecific-Based Combinations in MM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 27th 2023

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Treatment Selection of Bispecifics in Relapsed-Refractory MM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 27th 2023

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Treatment Approaches for Patients with Relapsed-Refractory MM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 20th 2023

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Final Thoughts on Transplant-Ineligible Patients with MM

ByRobert Z. Orlowski, MD, PhD,C. Ola Landgren, MD, PhD,Amrita Y. Krishnan, MD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 20th 2023

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Review of Patient Subgroups in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 13th 2023

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Clinical Trials in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 13th 2023

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

Induction Therapy in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Role of Transplant and Induction Therapies in NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

DETERMINATION, GRIFFIN, and MASTER Studies

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

January 30th 2023

Expert panelists discuss recent data updates from the DETERMINATION, GRIFFIN, and MASTER studies.

Induction Regimen Options in Transplant-Eligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

January 30th 2023

Opening their discussion on transplant-eligible newly diagnosed multiple myeloma (NDMM), expert panelists review induction regimen options for patients.

Recap: A Review of the Treatment Landscape in Multiple Myeloma

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

December 6th 2022

A panel of experts discusses the treatment approaches to three clinical cases of multiple myeloma in the context of data presented at recent meetings and reviews how it can be applied to daily clinical practice.

The panel sits behind a desk, smiling at the camera.

Unmet Needs and Future Directions in Multiple Myeloma Treatment

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 25th 2022

The panel closes their discussions by highlighting current unmet needs in multiple myeloma treatment and what excites them on the horizon.

CAR T-Cell Therapy in Multiple Myeloma Treatment

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 25th 2022

Dr Patel continues the conversation of novel treatments with an examination of CAR T-cell therapies in multiple myeloma.

Novel Bispecific Agents in the Treatment of Multiple Myeloma

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 17th 2022

Amrita Krishnan, MD, and Krina Patel, MD, review promising bispecific agents under investigation for multiple myeloma treatment.

Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 17th 2022

Dr Krina Patel presents the case of a relatively young patient with relapsed multiple myeloma, and Dr Caitlin Costello shares her approaches to treating relapsed/refractory multiple myeloma in her clinical practice.

Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 10th 2022

The panel explains their goals of treatment for older patients with transplant-ineligible multiple myeloma, and how they determine treatment duration.

Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 10th 2022

Rafael Fonseca, MD, and Krina Patel, MD, discuss the standard treatment approaches for frail or elderly patients with transplant-ineligible multiple myeloma.

First-Line Treatment Options in Transplant-Ineligible NDMM

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 4th 2022

Dr Caitlin Costello presents the case of a patient with transplant-ineligible multiple myeloma and sparks a conversation on the available treatment regimens.

Measuring Treatment Response in Transplant-Eligible NDMM

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

November 4th 2022

A look at how to measure an adequate treatment response in patients with transplant-ineligible newly-diagnosed multiple myeloma, and treatment regimens for high-risk patients.

Selecting a Treatment Regimen for Patients with Transplant-Eligible NDMM

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

October 27th 2022

A panel of experts discusses whether all patients with multiple myeloma should undergo transplant, and how to select the optimal treatment regimens for the treatment of transplant-eligible newly-diagnosed multiple myeloma.

Induction Regimen Options for Patients with Transplant-Eligible NDMM

ByRafael Fonseca, MD,Amrita Y. Krishnan, MD,Caitlin Costello, MD,Krina K. Patel, MD, MSc

October 27th 2022

Amrita Krishnan, MD, presents the case of a 63-year-old woman with transplant-eligible newly-diagnosed multiple myeloma, and Caitlin Costello, MD, describes the design and outcomes of recent trials in the transplant eligible setting.